Effect of Sulodexide in Early Diabetic Nephropathy
The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria
Sponsor: Collaborative Study Group (CSG)
Listed as NCT00130208, this PHASE3 trial focuses on Diabetic Nephropathy and remains completed. Sponsored by Collaborative Study Group (CSG), it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Collaborative Study Group (CSG)
- Keryx Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .